Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Optimising the accuracy of HIV drug resistance assays.

Karim SSA.

Lancet HIV. 2018 Nov;5(11):e608-e609. doi: 10.1016/S2352-3018(18)30211-X. Epub 2018 Sep 30. No abstract available.

PMID:
30282604
2.

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.

McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, Nagelkerke N, Garcia Lerma JG, Kashuba AD, Masson L, Mansoor LE, Karim QA, Karim SSA, Passmore JS.

Nat Med. 2018 May;24(4):491-496. doi: 10.1038/nm.4506. Epub 2018 Feb 26.

3.

Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.

Syam YM, El-Karim SSA, Nasr T, Elseginy SA, Anwar MM, Kamel MM, Ali HF.

Mini Rev Med Chem. 2019;19(3):250-269. doi: 10.2174/1389557517666170828121018.

PMID:
28847268
4.

Closing the NIH Fogarty Center threatens US and global health.

Karim SSA, Karim QA, Abimiku A, Bekker LG, Bukusi EA, Deschamps MMH, Derbew M, Garcia PJ, Gray G, Kamya MR, Swaminathan S, Wu Z.

Lancet. 2017 Jul 29;390(10093):451. doi: 10.1016/S0140-6736(17)31912-8. Epub 2017 Jul 27. No abstract available.

PMID:
28792403
5.

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C.

J Virol. 2017 Aug 24;91(18). pii: e00828-17. doi: 10.1128/JVI.00828-17. Print 2017 Sep 15. Erratum in: J Virol. 2018 Apr 13;92 (9):.

6.

Trump's "global gag rule": implications for human rights and global health.

Singh JA, Karim SS.

Lancet Glob Health. 2017 Apr;5(4):e387-e389. doi: 10.1016/S2214-109X(17)30084-0. No abstract available.

7.

Acceptability of Early Antiretroviral Therapy Among South African Women.

Garrett N, Norman E, Leask K, Naicker N, Asari V, Majola N, Karim QA, Karim SSA.

AIDS Behav. 2018 Mar;22(3):1018-1024. doi: 10.1007/s10461-017-1729-2.

8.

Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.

de Oliveira T, Kharsany AB, Gräf T, Cawood C, Khanyile D, Grobler A, Puren A, Madurai S, Baxter C, Karim QA, Karim SS.

Lancet HIV. 2017 Jan;4(1):e41-e50. doi: 10.1016/S2352-3018(16)30186-2. Epub 2016 Dec 1.

9.

Assessing progress with HIV incidence in national cohorts.

Karim SS.

Lancet HIV. 2017 Feb;4(2):e56-e58. doi: 10.1016/S2352-3018(16)30187-4. Epub 2016 Nov 16. No abstract available.

PMID:
27863999
10.

Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.

Naicker N, Naidoo A, Werner L, Garrett N, Majola N, Asari V, Baxter C, Grobler A, Karim QA, Karim SSA.

Antivir Ther. 2017;22(4):287-293. doi: 10.3851/IMP3106. Epub 2016 Nov 4.

PMID:
27835613
11.

Classification and Surgical Repair of Injuries Sustained During Transvenous Lead Extraction.

Bashir J, Fedoruk LM, Ofiesh J, Karim SS, Tyers GF.

Circ Arrhythm Electrophysiol. 2016 Sep;9(9). pii: e003741. doi: 10.1161/CIRCEP.115.003741.

PMID:
27625167
12.

SYNTHESIS, BIOLOGICAL EVALUATION AND MOLECULAR DOCKING STUDIES OF AROMATIC SULFONAMIDE DERIVATIVES AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS.

Abbas HS, Abdel-Karim SS, Ahmed EM, Eweas AF, El-Awdan SA.

Acta Pol Pharm. 2016 Sep;73(5):1163-1180.

PMID:
29638057
13.

Malignancy in Solitary Thyroid Nodule.

Majumder KR, Karmakar R, Karim SS, Al-Mamun A.

Mymensingh Med J. 2016 Jan;25(1):39-44.

PMID:
26931247
14.

Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women.

Mkhize NN, Durgiah R, Ashley V, Archary D, Garrett NJ, Karim QA, Karim SS, Moore PL, Yates N, Passmore JA, Tomaras GD, Morris L.

AIDS. 2016 Apr 24;30(7):1005-14. doi: 10.1097/QAD.0000000000001038.

15.

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

Archary D, Seaton KE, Passmore JS, Werner L, Deal A, Dunphy LJ, Arnold KB, Yates NL, Lauffenburger DA, Bergin P, Liebenberg LJ, Samsunder N, Mureithi MW, Altfeld M, Garrett N, Karim QA, Karim SA, Morris L, Tomaras GD.

Mucosal Immunol. 2016 May;9(3):821-833. doi: 10.1038/mi.2015.145. Epub 2016 Jan 27. Erratum in: Mucosal Immunol. 2016 May;9(3):834.

16.

Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.

Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, Sutherland LL, Scearce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks R, Eaton A, Foulger A, Nie X, Karim SSA, Barnett S, Kelsoe G, Kepler TB, Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison SC, Haynes BF.

Cell Rep. 2016 Jan 5;14(1):43-54. doi: 10.1016/j.celrep.2015.12.017. Epub 2015 Dec 24.

17.

Parathyroid Carcinoma in a 10 Years Old Female Child.

Rahman MM, Karim SS, Joarder AI, Mubin S, Abir MM, Morshed MS.

Mymensingh Med J. 2015 Jul;24(3):619-23.

PMID:
26329966
18.

Restoration of CD4+ Responses to Copathogens in HIV-Infected Individuals on Antiretroviral Therapy Is Dependent on T Cell Memory Phenotype.

Riou C, Tanko RF, Soares AP, Masson L, Werner L, Garrett NJ, Samsunder N, Karim QA, Karim SSA, Burgers WA.

J Immunol. 2015 Sep 1;195(5):2273-2281. doi: 10.4049/jimmunol.1500803. Epub 2015 Jul 20.

19.

Defeating AIDS--advancing global health.

Piot P, Abdool Karim SS, Hecht R, Legido-Quigley H, Buse K, Stover J, Resch S, Ryckman T, Møgedal S, Dybul M, Goosby E, Watts C, Kilonzo N, McManus J, Sidibé M; UNAIDS–Lancet Commission.

Lancet. 2015 Jul 11;386(9989):171-218. doi: 10.1016/S0140-6736(15)60658-4. Epub 2015 Jun 24. Review. No abstract available. Erratum in: Lancet. 2015 Jul 11;386(9989):136.

PMID:
26117719
20.

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.

Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L.

Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.

21.

Primary malignant melanoma of the penis with secondary to adrenal.

Islam MR, Siddique MI, Joarder AI, Ahmed SU, Karim SS, Hossain MJ.

Mymensingh Med J. 2015 Jan;24(1):195-8.

PMID:
25725691
22.

Appeal to global donors to save the Treatment Action Campaign.

Piot P, Barré-Sinoussi F, Karim QA, Karim SS, Beyrer C.

Lancet. 2014 Dec 6;384(9959):e62. doi: 10.1016/S0140-6736(14)62045-6. Epub 2014 Dec 2. No abstract available.

PMID:
25479693
23.

Early failure of the Biotronik Linox implantable cardioverter defibrillator lead.

Padfield GJ, Steinberg C, Karim SS, Tung S, Bennett MT, Le Maitre JP, Bashir J.

J Cardiovasc Electrophysiol. 2015 Mar;26(3):274-81. doi: 10.1111/jce.12583. Epub 2014 Dec 22.

PMID:
25404263
24.

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.

Succop SM, MacQueen KM, van Loggerenberg F, Majola N, Karim QA, Karim SS.

AIDS Care. 2014;26(12):1521-5. doi: 10.1080/09540121.2014.938014.

25.

Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.

Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF.

Cell Host Microbe. 2014 Sep 10;16(3):304-13. doi: 10.1016/j.chom.2014.08.006.

26.

HIV infection in high school students in rural South Africa: role of transmissions among students.

Kharsany AB, Buthelezi TJ, Frohlich JA, Yende-Zuma N, Samsunder N, Mahlase G, Williamson C, Travers SA, Marais JC, Dellar R, Karim SS, Karim QA.

AIDS Res Hum Retroviruses. 2014 Oct;30(10):956-65. doi: 10.1089/AID.2014.0110. Epub 2014 Sep 4.

27.

Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Mansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, Amico KR, Fisher J, Fisher WA, Macqueen KM, Karim SS.

AIDS Behav. 2014 May;18(5):841-8. doi: 10.1007/s10461-014-0752-9.

28.

Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.

Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, Kashuba AD, Karim QA, Karim SS.

AIDS Behav. 2014 May;18(5):820-5. doi: 10.1007/s10461-014-0749-4.

29.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.

Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium.

Virol J. 2013 Dec 2;10:347. doi: 10.1186/1743-422X-10-347.

30.

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Karim SS.

Antivir Ther. 2014;19(2):161-9. doi: 10.3851/IMP2701. Epub 2013 Oct 31.

31.

HIV pre-exposure prophylaxis in injecting drug users.

Karim SS.

Lancet. 2013 Jun 15;381(9883):2060-2. doi: 10.1016/S0140-6736(13)61140-X. Epub 2013 Jun 13. No abstract available.

PMID:
23769217
32.

Changes in Natural Killer cell activation and function during primary HIV-1 Infection.

Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH.

PLoS One. 2013;8(1):e53251. doi: 10.1371/journal.pone.0053251. Epub 2013 Jan 9.

33.

Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.

Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, Treurnicht F, Hraber P, Riou C, Gray C, Ferrari G, Tanner R, Ping LH, Anderson JA, Swanstrom R; CHAVI Core B, Cohen M, Karim SS, Haynes B, Borrow P, Perelson AS, Shaw GM, Hahn BH, Williamson C, Korber BT, Gao F, Self S, McMichael A, Goonetilleke N.

J Clin Invest. 2013 Jan;123(1):380-93. doi: 10.1172/JCI65330. Epub 2012 Dec 10.

34.

Health in South Africa: changes and challenges since 2009.

Mayosi BM, Lawn JE, van Niekerk A, Bradshaw D, Abdool Karim SS, Coovadia HM; Lancet South Africa team.

Lancet. 2012 Dec 8;380(9858):2029-43. doi: 10.1016/S0140-6736(12)61814-5. Epub 2012 Nov 30.

PMID:
23201214
35.

Sustainability of task-shifting for antiretroviral treatment.

Naranbhai V, Karim QA, Naidoo K, Yende-Zuma N, Karim SS.

Lancet. 2012 Dec 1;380(9857):1907-8; author reply 1908. doi: 10.1016/S0140-6736(12)62110-2. No abstract available.

36.

HIV prevalence among high school learners - opportunities for school-based HIV testing programmes and sexual reproductive health services.

Kharsany AB, Mlotshwa M, Frohlich JA, Zuma NY, Samsunder N, Karim SS, Karim QA.

World Health Popul. 2012;13(4):43-50.

PMID:
23089727
37.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
38.

Antiretroviral prophylaxis for HIV prevention reaches a key milestone.

Karim SS, Karim QA.

Lancet. 2012 Jun 2;379(9831):2047-8. doi: 10.1016/S0140-6736(12)60786-7. Epub 2012 May 18. No abstract available.

PMID:
22608193
39.

Malignancy in solitary solid cold thyroid nodule.

Fariduddin M, Amin AH, Ahmed MU, Karim SS, Moslem F, Kamal M.

Mymensingh Med J. 2012 Apr;21(2):276-80.

PMID:
22561771
40.

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.

Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams MR, Bandawe G, Swanstrom R, Karim QA, Karim SS, Williamson C.

J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2.

41.

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.

Sibeko S, Baxter C, Yende N, Karim QA, Karim SS.

Obstet Gynecol. 2011 Oct;118(4):895-904. doi: 10.1097/AOG.0b013e31822be512.

42.

Antiretroviral prophylaxis: a defining moment in HIV control.

Karim SS, Karim QA.

Lancet. 2011 Dec 17;378(9809):e23-5. doi: 10.1016/S0140-6736(11)61136-7. Epub 2011 Jul 21. No abstract available.

43.

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

Karim SS, Kashuba AD, Werner L, Karim QA.

Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7. No abstract available.

44.

HIV prevention transformed: the new prevention research agenda.

Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi SM, Schwartländer B, Cohen MS.

Lancet. 2011 Jul 16;378(9787):269-78. doi: 10.1016/S0140-6736(11)60877-5. Review.

45.

Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women.

Ramsuran V, Kulkarni H, He W, Mlisana K, Wright EJ, Werner L, Castiblanco J, Dhanda R, Le T, Dolan MJ, Guan W, Weiss RA, Clark RA, Karim SS, Ahuja SK, Ndung'u T.

Clin Infect Dis. 2011 May;52(10):1248-56. doi: 10.1093/cid/cir119.

46.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

47.

Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.

Karim QA, Kharsany AB, Naidoo K, Yende N, Gengiah T, Omar Z, Arulappan N, Mlisana KP, Luthuli LR, Karim SS.

Contemp Clin Trials. 2011 May;32(3):333-8. doi: 10.1016/j.cct.2011.01.005. Epub 2011 Jan 26.

48.

Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection.

Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Karim SS, Brass AL, Ndung'u T; CAPRISA Acute Infection Study Team.

J Virol. 2011 Jan;85(1):208-16. doi: 10.1128/JVI.01810-10. Epub 2010 Oct 27.

50.

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L.

Virology. 2010 Jun 20;402(1):187-96. doi: 10.1016/j.virol.2010.03.021. Epub 2010 Apr 13.

Supplemental Content

Loading ...
Support Center